SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TLX

Telix Pharmaceuticals Ltd (NASDAQ:TLX)

Australia · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.37-$0.34 (-3.90%)
 
Market cap
$2.84B
Insider Score
Analyst consensus
Market Cap$2.84B-4.6%
Revenue (ttm)$890.79M
Net Income$33.50M
EPS$0.10
Shares Out339.78M
PE Ratio83.70
Forward PE-313.37
Dividendn/a
Ex-Dividend Daten/a
Volume269,432
Open$8.66
Previous Close$8.71
Day's Range$8.37 - $8.70
52-Week Range$6.28 - $13.11
Beta0.63
Analystsnone
Price Target$19.37(+131.37%)
Earnings Daten/a
-3.90% (1D)
No price history available.

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Address
55 Flemington Road, North Melbourne, VIC, 3051, Australia
Market Cap
2.84 billion
Employees
1,120
Industrial Classification
Biotechnology

Telix Pharmaceuticals Ltd Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
21st Percentile Overall Score
TLX InsiderScore:54 / 99

Telix Pharmaceuticals Ltd scored higher than 21% of companies evaluated by InsiderBuying, and ranked 71st out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Telix Pharmaceuticals Ltd bought $20.0K of stock across 1 purchase in the last 90 days, the largest of them $20.0K.

Stake Increase

The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$1.02M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 Sell

2 firms rating TLX in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-3.90%
5 Days
-9.32%
1 Month
-12.26%
6 Months
-11.62%
1 Year
-4.56%

$TLX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TLX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TLX's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TLX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New TLX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TLX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from TLX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
54.09
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$1.02M
Distinct Buyers
2

Insider Score Trend Over Time

+10.1 since Sep 24
0255075100Sep 24 — Insider Score 44.0Sep 25 — Insider Score 68.4Sep 26 — Insider Score 67.9Sep 27 — Insider Score 68.1Sep 28 — Insider Score 68.2Sep 29 — Insider Score 67.8Sep 30 — Insider Score 67.5Oct 1 — Insider Score 66.5Oct 2 — Insider Score 45.0Oct 3 — Insider Score 66.3Oct 4 — Insider Score 66.5Oct 5 — Insider Score 66.6Oct 6 — Insider Score 65.7Oct 7 — Insider Score 65.4Oct 8 — Insider Score 65.1Oct 9 — Insider Score 64.9Oct 10 — Insider Score 64.4Oct 11 — Insider Score 65.5Oct 12 — Insider Score 65.7Oct 13 — Insider Score 65.4Oct 14 — Insider Score 66.0Oct 15 — Insider Score 65.9Oct 16 — Insider Score 65.8Oct 17 — Insider Score 65.7Oct 18 — Insider Score 66.1Oct 19 — Insider Score 65.0Oct 20 — Insider Score 65.0Oct 21 — Insider Score 65.8Oct 22 — Insider Score 65.8Oct 23 — Insider Score 65.7Oct 24 — Insider Score 65.7Oct 25 — Insider Score 65.3Oct 26 — Insider Score 65.4Oct 27 — Insider Score 65.4Oct 28 — Insider Score 65.5Oct 29 — Insider Score 65.2Oct 30 — Insider Score 64.2Oct 31 — Insider Score 63.8Nov 1 — Insider Score 64.0Nov 2 — Insider Score 64.1Nov 3 — Insider Score 63.6Nov 4 — Insider Score 63.3Nov 5 — Insider Score 62.6Nov 6 — Insider Score 61.8Nov 7 — Insider Score 61.2Nov 8 — Insider Score 62.1Nov 9 — Insider Score 62.6Nov 10 — Insider Score 61.5Nov 11 — Insider Score 60.6Nov 12 — Insider Score 60.6Nov 13 — Insider Score 59.4Nov 14 — Insider Score 58.7Nov 15 — Insider Score 59.2Nov 16 — Insider Score 59.2Nov 17 — Insider Score 57.7Nov 18 — Insider Score 56.9Nov 19 — Insider Score 55.8Nov 20 — Insider Score 54.4Nov 21 — Insider Score 53.8Nov 22 — Insider Score 54.1Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IVSIApplied Finance IVS International Large ETF0.36%
JHMDJohn Hancock Investments - Multifactor Developed International ETF0.10%
APIEActivePassive International Equity ETF0.01%

Weight is the stock’s share of each fund’s holdings.